Compare
Axogen, Inc. vs InMode Ltd. vs Outset Medical, Inc. vs Ceribell, Inc.
| Latest fiscal year | Axogen, Inc. AXGN | InMode Ltd. INMD | Outset Medical, Inc. OM | Ceribell, Inc. CBLL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $225.21M | $370.50M | $119.48M | $89.06M |
| Revenue growth (YoY) | +20.2% | -6.2% | +5.1% | +36.1% |
| Gross margin | 74.3% | 78.5% | 39.1% | 87.9% |
| Operating margin | -3.5% | 23.0% | -55.8% | -65.6% |
| Net margin | -7.0% | 25.3% | -68.3% | -60.0% |
| Net income | -$15.70M | $93.83M | -$81.65M | -$53.41M |
| EPS (Diluted) | -$0.34 | $1.43 | -$5.37 | -$1.46 |
| Operating cash flow | $812.0K | $85.26M | -$46.33M | -$40.81M |
| Free cash flow | -$2.93M | $84.28M | -$47.12M | -$41.58M |
| Cash & equivalents | $35.55M | $302.54M | $35.01M | $40.48M |
| Total assets | $221.69M | $766.43M | $264.50M | $195.80M |
| Total liabilities | $92.84M | $83.23M | $137.54M | $40.47M |
| Shareholders' equity | $128.85M | $683.20M | $126.95M | $155.34M |
| Return on year-end equity | -12.2% | 13.7% | -64.3% | -34.4% |
| Shares outstanding | 47.20M | 63.36M | 18.17M | 37.49M |
Revenue, most recent five fiscal years
| Fiscal year | Axogen, Inc. | InMode Ltd. | Outset Medical, Inc. | Ceribell, Inc. |
|---|---|---|---|---|
| Latest | $225.21M Ended 2025-12-31 | $370.50M Ended 2025-12-31 | $119.48M Ended 2025-12-31 | $89.06M Ended 2025-12-31 |
| 1 year earlier | $187.34M Ended 2024-12-31 | $394.82M Ended 2024-12-31 | $113.69M Ended 2024-12-31 | $65.44M Ended 2024-12-31 |
| 2 years earlier | $159.01M Ended 2023-12-31 | $492.05M Ended 2023-12-31 | $130.38M Ended 2023-12-31 | $45.23M Ended 2023-12-31 |
| 3 years earlier | $138.58M Ended 2022-12-31 | $454.27M Ended 2022-12-31 | $115.38M Ended 2022-12-31 | n/a |
| 4 years earlier | $127.36M Ended 2021-12-31 | $357.56M Ended 2021-12-31 | $102.60M Ended 2021-12-31 | n/a |